InvestorsObserver
×
News Home

VBL Therapeutics (VBLT) Gets Clearance to Continue The OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

Friday, September 17, 2021 12:13 PM | Michael Hayne

Mentioned in this article

VBL Therapeutics (VBLT) Gets Clearance to Continue The OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

What's Going On With VBL Therapeutics?

VBL Therapeutics (VBLT) today announced the independent Data Safety Monitoring Committee (DSMC) of the ongoing OVAL Phase 3 registration-enabling study of VB-111 in ovarian cancer. Shares of the company were trading lower -0.90% to $2.36 a share on Friday.

What Does This Mean For VBL Therapeutics?

The DSMC for the OVAL trial is required to impose standards of safety, monitoring the standards’ implementation for the trial participants and treatment efficacy data, and advocating on the patient's behalf.

The  OVAL trial will involve 400 adult patients globally, though 320 patients have already been recruited. The trial has two primary endpoints: progression free survival (PFS) and overall survival (OS).

“We continue to be very pleased to learn that data collected to date in the OVAL clinical trial has passed independent DSMC review as we progress toward our enrollment goal,” said Prof. Dror Harats, M.D., chief executive officer of VBL Therapeutics. Adding, “We thank the DSMC for its ongoing diligence, guidance and support.”

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications.

Overall Score - 70

VBLT has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on VBLT!

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

To see InvestorsObserver's full report on VBLT Click Here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App